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Abstract: The current chemotherapy of Chagas disease needs to be urgently improved. With this 
aim, a series of 16 hybrids of Cinchona alkaloids and bile acids were prepared by functionalization 
at position C-2 of the quinoline nucleus by a radical attack of a norcholane substituent via a Barton–
Zard decarboxylation reaction. The antitrypanosomal activity of the hybrids was tested on different 
stages and strains of T. cruzi. In particular, eight out of 16 hybrids presented an IC50 ≤1 μg/mL against 
trypomastigotes of the CL Brener strain and/or a selectivity index higher than 10. These promising 
hybrids yielded similar results when tested on trypomastigotes from the RA strain of T. cruzi 
(discrete typing unit—DTU—VI). Surprisingly, trypomastigotes of the Y strain (DTU II) were more 
resistant to benznidazole and to most of the hybrids than those of the CL Brener and RA strains. 
However, the peracetylated and non-acetylated forms of the cinchonine/chenodeoxycholic bile acid 
conjugate 4f and 5f were the most trypanocidal hybrids against Y strain trypomastigotes, with IC50 
values of 0.5 and 0.65 μg/mL, respectively. More importantly, promising results were observed in 
invasion assays using the Y strain, where hybrids 5f and 4f induced a significant reduction in 
intracellular amastigotes and on the release of trypomastigotes from infected cells.  




The current pharmacological treatment (i.e., benznidazole (Bz) and nifurtimox (Nf)) against 
Trypanosoma cruzi, the etiological agent of Chagas disease, are highly toxic and not effective, 
especially during the chronic stage of the disease. In order to find alternative treatments against the 
disease, numerous studies have shown that quinoline derivatives display cytotoxic activity against 
different protozoan parasites [1–6]. A unique class of quinoline alkaloids are the Cinchona cinchona 
alkaloids, which includes quinine, quinidine, cinchonidine, and cinchonine. These naturally 
occurring compounds have all shown some degree of anti-parasitic activity, especially against 
Plasmodium falciparum. In particular, quinidine is the most active antiprotozoal alkaloid of this family 
and has been used for more than 400 years for the treatment of malaria [7]. 
Molecules 2019, 24, 3168 2 of 10 
 
With the strategy of combining the anti-parasitic properties of natural Cinchona alkaloids [8] with 
the known properties of bile acids as drug transporters [9], a series of 16 hybrids of Cinchona alkaloids 
and bile acids were prepared via a Barton–Zard decarboxylation reaction [10] (Table 1). Briefly, 
quinine, quinidine, cinchonine and cinchonidine were functionalized at position C-2 of the quinoline 
nucleus by a radical attack of a norcholane substituent. All the hybrids showed antiplasmodial 
activity (IC50 ≤ 6 μg/mL), particularly those containing a nor-chenodeoxycholane moiety (4b, 4d, 4f, 
4h, 5b, 5d, 5f, 5h) with IC50 values comparable to those of the natural alkaloids and selectivity indices 
in the range of 5.6–15.7 [10]. In addition, seven compounds (4d, 4f, 4h, 5b, 5d, 5f, 5h) showed 
promising trypanocidal activity against T. brucei, with IC50 values in the same range as the commercial 
drug suramin [10]. These results prompted us to evaluate the anti-trypanosomal activity of the 
hybrids against different strains and stages of Trypanosoma cruzi. 
Table 1. Hybrids of Cinchona alkaloids and bile acids were prepared via a Barton–Zard 
decarboxylation reaction. 
Hybrid (Alkaloyd + Bile Acid) Peracetylated Non-Acetylated 
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A series of 16 hybrids of Cinchona alkaloids and bile acids were prepared via a Barton–Zard 
decarboxylation reaction, as previously described [10]. With the aim of evaluating the anti-
trypanosomal differential activity of the hybrids on different stages and strains of T. cruzi, the hybrids 
were first tested on trypomastigotes of the reference strain of T. cruzi, the CL Brener strain. In parallel, 
cytotoxicity was assayed on NRK cells, a cell line that we have used as an infection model in the past 
[11]. To this end, the trypomastigotes and NRK cells were incubated with increasing concentrations 
of the hybrids and the calculated IC50 values (Table 2). All the hybrids showed some degree of 
trypanosomal activity. In particular, eight compounds—including the peracetylated and non-
acetylated forms of the quinidine/litocholic bile acid conjugate (4c and 5c), the 
cinchonine/chenodeoxycholic bile acid conjugate (4f and 5f), and the cinchonidine/litocholic bile acid 
conjugate (4g and 5g), as well as the peracetylated form of the cinchonidine/chenodeoxycholic bile 
acid conjugate (4h) and the non-acetylated form of the cinchonin/litocholic bile acid (5e)—displayed 
IC50 values below 1 μg/mL and/or selectivity indices of greater than 10 (Table 2, in grey). 
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Table 2. IC50 values for trypomastigotes and NRK cells were determined as described in Materials and 
Methods. The selectivity index (SI) was calculated as IC50NRK/IC50 parasite. Hybrids with an IC50 close 
to 1 μg/mL and/or a selectivity higher then 10 (in grey) were selected as cytotoxic studies using other 
strains and for infection assays (see text). ND: Not Determined. 
 T. cruzi CL Brener NRK Cells Selectivity 
Hybrid IC50 (μg/mL) IC50 (μg/mL)  NRK/T. cruzi 
5b 0.90 ± 0.10 5.10 ± 0.76 5.67  
4b 0.80 ± 0.13 3.91 ± 0.29 4.89  
5a 3.71 ± 0.13 15.30 ± 4.04 4.12  
4a 0.64 ± 0.15 1.41 ± 0.13 2.20  
5d 0.40 ± 0.05 1.59 ± 0.54 3.98  
4d 0.72 ± 0.07 3.30 ± 0.08 4.58  
5c 0.78 ± 0.11 >11 >10  
4c 1.08 ± 0.23 16.53 ± 0.18 15.30  
5f 0.34 ± 0.03 4.02 ± 0.55 12.18 
4f 0.51 ± 0.06 6.69 ± 1.51 13.04  
5e 3.96 ± 2.69 >30 ND 
4e 1.16 ± 0.15 7.50±0.29 6.46 
5h 0.30 ± 0.00 0.67±0.05 2.23  
4h 0.70 ± 0.18 6.50 ± 0.28 9.28 
5g 2.56 ± 0.58 27.11 ± 4.54 10.58  
4g 1.30 ± 0.01 12.30 ± 0.81 9.46 
Bz 2.5 ± 0.01 ND ND 
Because of the high genetic variability and phenotypic diversity that T. cruzi presents, the 
parasite has been classified into six genetic groups (discrete typing units, DTUs) named TcI–TcVI 
[12]. The DTUs present different eco-epidemiological, clinical, and geographic associations, with 
several genetic molecular markers that are being used to classify the strains after their isolation from 
biological samples [12]. As a consequence of this variability, in vitro and in vivo differential drug 
susceptibility among strains has been reported [13–17]. Taking this into account, hybrids presenting 
an IC50 ≤ 1 μg/mL and/or a selectivity index (SI) ≥ 10 from the screening with CL Brener, were tested 
on trypomastigotes from the Y and the RA strains of T. cruzi (DTU II and VI, respectively) (Table 3). 
Trypomastigotes of the RA strain (DTU VI) showed a similar response to the treatment with the 
hybrids than those of the CL Brener strain, which is another member of the DTU VI. On the other 
hand, the Y strain (DTU II) was more resistant to the control drug, the commercial available Bz, and 
most of the assayed hybrids. However, the peracetylated and non-acetylated forms of the 
cinchonine/chenodeoxycholic bile acid conjugates 4f and 5f had IC50 values of 0.50 and 0.65 μg/mL, 
respectively, against Y strain trypomastigotes. It is noteworthy that these results represented a 20–
30-fold difference compared to the IC50 value of Bz. 
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Table 3. Hybrid IC50 values for T. cruzi tripomastigote strains from different discrete typing units 
(DTUs). 
 T. cruzi RA (DTU VI) T. cruzi Y (DTU II) 
Hybrid IC50 (μg/mL) IC50 (μg/mL)  
5c 0.79 ± 0.19 ≥2.00 
4c ND ≥1.00 
5f 0.31 ± 0.10 0.65 ± 0.07 
4f 0.25 ± 0.10 0.50 ± 0.03 
4h 1.50 ± 0.50 ≥2.00 
5g 3.03 ± 0.24 3.25 ± 0.67 
4g 1.10 ± 0.21 3.05 ± 0.71 
Bz 2.5 ± 0.32 ≥15.00 
Not only the genetic diversity among strains should be taken into account while searching for 
new drugs. Differential susceptibility of the different life cycle stages of the parasite within the same 
strain [18] should be also considered. In this regard, Bz and Nf effectiveness against axenic 
epimastigotes and the intracellular stages of T. cruzi have been already reported [19]. Furthermore, 
drug sensitivity exhibited by the extracellular forms (i.e., epimastigotes and trypomastigotes) could 
sometimes be higher than the sensitivity of the intracellular form of the parasite, in part because of 
its intracellular availability [20] More importantly, given that in the chronic phase of Chagas disease, 
current chemotherapy is not efficient and that parasitemia is usually low, performing new drug 
screenings on the intracellular replicative stage of the parasite appears to be the better approach. To 
confirm their anti-parasitic activity, nine of the hybrids were evaluated against intracellular 
amastigotes of the Y strain at the IC50 found for trypomastigotes of the same strain. Briefly, 
trypomastigotes were incubated with NRK cells and left to infect for two hours. After the infection 
period, free trypomastigotes were removed from the medium, monolayers were washed, and media 
containing the final concentration of the drug were added. Forty-eight hours post infection, cells were 
fixed and stained, and amastigotes/100 cells were calculated. As shown in Figure 1A, B, a significant 
reduction in intracellular amastigotes was observed for the hybrids 4f and 5f compared to untreated 
infected cells.  
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Figure 1. (A) Effects of hybrids on intracellular amastigotes. Hybrids were evaluated at the estimated 
parasite IC50 concentration for the Y strain (Table 3). Bars indicate mean ± SE of at least three 
independent assays (see Methods). * p < 0.05, **p < 0.01. (B) Representative microscope photographs 
of NRK infected cells treated as indicated. 
To fully eliminate the intracellular parasite, a trypanocidal drug action is ideally desired. For 
trypanostatic drugs, a longer chemotherapy is required to allow the elimination of the intracellular 
parasite, since the anti-parasitic effect could be reversed upon removal of the drug. In order to 
characterize the antiparasitic features of the hybrids, our strategy was to remove the hybrids from 
the medium of infected NRK cells and let the infection develop. In this approach, after the two hour 
infection of NRK cells with trypomastigotes of the Y strain, compounds were added and left for 72 
hours before being replaced with fresh medium without drugs. Six days post infection, the 
trypomastigotes released to the supernatant were quantified. Two different scenarios were expected: 
1) Upon removal of a trypanostatic hybrid, intracellular amastigotes would proliferate, and a higher 
trypomastigote release, close to control with no hybrid, would be observed; or 2) the hybrids would 
have a trypanocidal effect and non-viable amastigotes would not be able to proliferate, so the 
trypomastigote count would decrease. The results from Figure 2 clearly indicate that amastigotes 
could not recover from the 72 hours of treatment with hybrids 5f and 4f, since the trypomastigote 
count in the supernatant of infected cells was significantly lower than non-treated control.  
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Figure 2. Hybrid activity on trypomastigote release at day six post infection. Cells treated with the 
indicated concentration of benznidazol (A) or the hybrids compounds 5f (B) or 4f (C). Bars indicate 
mean ± ES of at least three independent assays (see Methods) *** p < 0.001. 
Overall, the results obtained with hybrids 4f and 5f are promising. These hybrids shown to be 
active against amastigotes of the Y strain, presenting a lower IC50 than Bz (Figure 1) and this anti-
parasitic action could not reverse upon removal of the hybrids (Figure 2). 
3. Discussion 
An alternative approach to the discovery of new drugs to treat old neglected diseases, such as 
trypanosomiasis, could be the synthesis of new bioactive compounds through hybridization. In 
particular, the synthesis of hybrids of bioactive compounds that combine the properties of their 
individual components has emerged as a fast growing methodology in medicinal chemistry [5,10,21]. 
Following the strategy of combining the anti-parasitic properties of natural Cinchona alkaloids with 
the known properties of bile acids as drug transporters, a series of 16 hybrids of Cinchona alkaloids 
and bile acids were prepared via a Barton–Zard decarboxylation reaction. It was previously shown 
that these hybrids have anti-plasmodial and anti-trypanosomal activity [10]. In addition to these 
results, in this work, we have shown the promising trypanocidal activity of the hybrids against 
trypomastigotes of different DTUs of T. cruzi, such as CL Brener, RA, and Y. The high genetic 
variability and phenotypic diversity among strains of T. cruzi can lead to differential susceptibilities 
to drugs, suggesting that a broader screening, including different strains from different DTUs, should 
be performed in the search of new therapeutic drugs. In fact, we observed that the trypomastigotes 
of the Y strain were more resistant than the trypomastigotes of the CL Brener and RA strains to Bz 
and most of the newly synthetized hybrids. However, hybrids 4f and 5f presented a strong activity 
against trypomastigotes of the Y strain, as well. More importantly, a significant anti-parasite activity 
was found when these hybrids were tested on Y strain amastigotes, the intracellular proliferative 
stage of the parasite. This activity was reflected in a significant reduction in the number of 
intracellular amastigotes per infected cell. In addition, the action of hybrids 4f and 5f appeared to be 
trypanocidal, since amastigotes could not recover to proliferate and differentiate when the infection 
was left to develop. This fact that was reflected in a decreased in the number free trypomastigotes in 
the supernatant of infected cells after removal of the hybrids.  
4. Materials and Methods 
4.1. Cells and Parasites 
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The NRK and Vero cell lines were routinely maintained in DMEM (Gibco) supplemented with 
10% SFB (Natocor) and Penicillin/Streptomicin (100 Units/0.1mg/mL, Sigma) at 37 °C and 5% CO2 
atmosphere. The trypomatigotes of T. cruzi strains CL Brener, Y, and RA were routinely maintained 
in Vero cells cultured in DMEM supplemented with 4% SFB and Penicillin/Streptomicin. The 
trypomastigotes of each strain were purified from infected Vero cells supernatants and used in the 
different assays. 
4.2. Parasite IC50 Estimation 
2 × 106/mL trypomastigotes were incubated with different concentrations of the hybrids, control 
drug or vehicle, by triplicate at 37 °C and 5% CO2 for 24 h. Next, trypomastigotes were counted in a 
Neubauer chamber. The IC50 ± SD (n = 3) were estimated using the “Dose–Response” module in 
Graphpad Prism. 
4.3. Cells IC50 Estimation 
1 × 105/mL NRK cells were grown overnight in a 96 multi-well plate. The culture medium was 
replaced by a culture medium containing increasing concentrations of hybrids, control drugs or 
vehicles, and cells incubated at 37 °C and 5% CO2 for 48 h. Next, cells were washed, fixed for 10 min 
with cold methanol (Sintorgan), and stained with violet crystal (Sigma 0.5% in methanol). After an 
exhaustive wash, cells were dried overnight. 10% acetic acid (Biopack) was added to each well, and 
the absorbance measured at 600 nm. Similarly, a standard curve was prepared (absorbance vs. 
increasing concentrations of NRK cells) to estimate the NRK IC50 using Graphpad Prism. 
4.4. Amastigote Count 
Infections were performed as previously described [11]. Briefly, NRK cells (growing on glass 
slides in a 24 multi-well plate) were infected for 2 h with trypomastigotes of the Y strain. After 
extensive washing, a medium containing compounds at the corresponding trypomastigote IC50 
concentration (see Table 1) was added. After 48 h of incubation, cells were fixed with 4% formalin, 
stained with DAPI and photographed in a fluorescence microscope (Olympus). The amastigotes/100 
cells were determined counting 1000 cells from each well (3000 cells/compound) using the ImageJ cell 
counter plugin.  
4.5. Trypomastigote Release Assay 
NRK cells were cultured and treated as described in Section 4.1. At day 3 post infection (pi), the 
medium with hybrids was replaced by fresh media (with 4% SFB). At day 6 pi, the released 
trypomastigotes in the supernatant of infected were counted using a Neubauer chamber.  
4.6. Statistics 
In all cases, 3 independent experiments were done by triplicate. In amastigotes count and 
trypomastigotes released from infected cells, the results are presented as normalized relative to 
control without drug. The mean ± SD of amastigotes/100 cells or trypomastigote released were 
calculated and analyzed with one-way ANOVA with Dunnett posttest performed with Graphpad 
Prism software. 
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